Inhibition of HIF1α signaling: A grand slam for MDS therapy?

Jiahao Chen, Ulrich Steidl

Research output: Contribution to journalArticlepeer-review

Abstract

The recent focus on genomics in myelodysplastic syndromes (MDS) has led to important insights and revealed a daunting genetic heterogeneity, which is presenting great challenges for clinical treatment and precision oncology approaches in MDS. Hayashi and colleagues show that multiple mutations frequently found in MDS activate HIF1α signaling, which they also found to be sufficient to induce overt MDS in mice. Furthermore, both genetic and pharmacologic inhibition of HIF1α suppressed MDS development with only mild effects on normal hematopoiesis, implicating HIF1α signaling as a promising therapeutic target to tackle the heterogeneity of MDS.

Original languageEnglish (US)
Pages (from-to)1355-1357
Number of pages3
JournalCancer discovery
Volume8
Issue number11
DOIs
StatePublished - Nov 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Inhibition of HIF1α signaling: A grand slam for MDS therapy?'. Together they form a unique fingerprint.

Cite this